Imatinib alone and in combination for chronic myeloid leukemia

Brian J. Druker

doi:10.1016/S0037-1963(03)70042-0

Imatinib alone and in combination for chronic myeloid leukemia

Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

98 Scopus citations

Abstract

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

Original language	English (US)
Pages (from-to)	50-58
Number of pages	9
Journal	Seminars in hematology
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/S0037-1963(03)70042-0
State	Published - Jan 2003

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/S0037-1963(03)70042-0

Cite this

@article{0482682bc8f247438adeb37500ff726b,

title = "Imatinib alone and in combination for chronic myeloid leukemia",

abstract = "Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.",

author = "Druker, {Brian J.}",

note = "Funding Information: Supported by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation. ",

year = "2003",

month = jan,

doi = "10.1016/S0037-1963(03)70042-0",

language = "English (US)",

volume = "40",

pages = "50--58",

journal = "Seminars in hematology",

issn = "0037-1963",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Imatinib alone and in combination for chronic myeloid leukemia

AU - Druker, Brian J.

N1 - Funding Information: Supported by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation.

PY - 2003/1

Y1 - 2003/1

N2 - Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

AB - Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0037254419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037254419&partnerID=8YFLogxK

U2 - 10.1016/S0037-1963(03)70042-0

DO - 10.1016/S0037-1963(03)70042-0

M3 - Review article

C2 - 12563611

AN - SCOPUS:0037254419

SN - 0037-1963

VL - 40

SP - 50

EP - 58

JO - Seminars in hematology

JF - Seminars in hematology

IS - 1

ER -

Imatinib alone and in combination for chronic myeloid leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this